An international systematic review and meta-analysis revealed that tirzepatide, a dual GIP and GLP-1 receptor agonist, achieves significant weight loss across patient groups with and without diabetes. This metabolic agent exhibits a favorable efficacy and safety profile, marking an advance in obesity treatment. The comprehensive analysis supports expanding tirzepatide’s clinical role beyond glycemic control.